Moleculin begins NIH-funded Phase II glioblastoma treatment trial [Yahoo! Finance]
Moleculin Biotech, Inc. (MBRX)
Last moleculin biotech, inc. earnings: 8/16 05:35 pm
Check Earnings Report
US:NASDAQ Investor Relations:
moleculin.com/investors
Company Research
Source: Yahoo! Finance
The trial is being conducted under Northwestern University's Investigative New Drug application, which references Moleculin's own US Food and Drug Administration (FDA)-cleared IND in April 2022. Apart from NIH, BrainUp, a non-profit organisation focusing on creating awareness on brain cancer, is providing additional funding. The open-label, multi-arm study is focusing on newly diagnosed patients with isocitrate dehydrogenase (IDH) wild-type, O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma. The primary goal of the study is to measure progression-free survival, while secondary outcomes include the analysis of the tumour microenvironment. WP1066, an immune/transcription modulator, is designed to enhance the immune response to tumours by hindering regulatory T cells' errant activity and oncogenic transcription factors. The asset obtained orphan drug designation for the treatment of brain tumours and rare pediatric disease designation for three other paed
Show less
Read more
Impact Snapshot
Event Time:
MBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBRX alerts
High impacting Moleculin Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
MBRX
News
- Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical TrialPR Newswire
- Moleculin Biotech, Inc. (NASDAQ: MBRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Moleculin to Present at the Virtual Investor Pitch ConferencePR Newswire
MBRX
Sec Filings
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- MBRX's page on the SEC website